START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Melanoma (Skin)|Triple-Negative Breast Cancer|Non-Small Cell Lung Cancer|Synovial Sarcoma|Myxoid Liposarcoma|Colorectal Cancer
Interventions: DRUG: PeptiCRAd-1|DRUG: Cyclophosphamide|DRUG: Pembrolizumab
Sponsor: Valo Therapeutics Oy